Jelle Vehof

Jelle Vehof

Auto-generated profile, based on publicly available information

Jelle Vehof

University of Groningen, University Medical Centre Groningen

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Ocular Surface
Verified
Journal Article
Closed access
JVJelle Vehof
Jelle Vehof
HSHarold Snieder
Harold Snieder
NJNomdo Jansonius
Nomdo Jansonius
CHChristopher J. Hammond
Christopher J. Hammond

5 May 2022 in Acta Ophthalmologica
Verified
Journal Article
Open access
... .
. .
MMMorten Magno
Morten Magno
RVRagnheidur R. Vernhardsdottir
Ragnheidur R. Vernhardsdottir
EMEmily Moschowits
Emily Moschowits
KTKim Alexander Tønseth
Kim Alexander Tønseth
TUTor P. Utheim
Tor P. Utheim
Dry eye disease (DED) is a highly prevalent and debilitating condition affecting several hundred million people worldwide. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan commonly used in the treatment of DED. This review aims to critically evaluate the literature on the safety and efficacy of artificial tears containing HA used in DED treatment. Literature searches were conducted in PubMed, including MEDLINE, and in EmbaseviaOvid with the search term: “(hyaluronic acid OR hyaluronan OR hyaluronate) AND (dry eye OR sicca)”. A total of 53 clinical trials are included in this review, including eight placebo‐controlled trials. Hyaluronic acid concentrations ranged from 0.1% to 0.4%. Studies lasted up to 3 months. A broad spectrum of DED types and severities was represented in the reviewed literature. No major complications or adverse events were reported. Artificial tears containing 0.1% to 0.4% HA were effective at improving both signs and symptoms of DED. Two major gaps in the literature have been identified: 1. no study investigated the ideal drop frequency for HA‐containing eyedrops, and 2. insufficient evidence was presented to recommend any specific HA formulation over another. Future investigations assessing the optimal drop frequency for different concentrations and molecular weights of HA, different drop formulations, including tonicity, and accounting for DED severity and aetiology are essential for an evidence‐based, individualized approach to DED treatment.

1 March 2017 in Ophthalmology
Verified
Journal Article
Closed access
JVJelle Vehof
Jelle Vehof
NSNicole Sillevis Smitt-Kamminga
Nicole Sillevis Smitt-Kamminga
SNSimone A. Nibourg
Simone A. Nibourg
CHChristopher J. Hammond
Christopher J. Hammond

1 July 2021 in The Ocular Surface
Verified
Journal Article
Open access
MMMathias Kaurstad Morthen
Mathias Kaurstad Morthen
MMMorten Schjerven Magno
Morten Schjerven Magno
TUTor Paaske Utheim
Tor Paaske Utheim
Harold SniederHarold Snieder
Harold Snieder
CHChristopher J. Hammond
Christopher J. Hammond
JVJelle Vehof
Jelle Vehof
This large cross-sectional population-based study investigated the relationship between dry eye disease (DED) and health-related quality of life (HR-QoL). Dry eye and HR-QoL were assessed in 78,165 participants (19-94 yrs, 59.2% female) from the Dutch population-based Lifelines cohort, using the WHS and the SF36 questionnaire, respectively. Logistic regression was used to assess the relationship between DED and below median Physical Component Summary (PCS) and Mental Component Summary (MCS) score, corrected for age, sex, education, BMI, and 52 comorbidities. Overall, 8.9% of participants had DED. Participants with DED had an increased risk of low PCS (OR 1.54 (95% CI 1.46-1.62)) and MCS scores (OR 1.39 (95% CI 1.32-1.46)), corrected for age and sex. This risk remained significant after correction for comorbidities (P < 0.0005). Increasing DED symptom frequency was associated with decreasing HR-QoL (P < 0.0005). Undiagnosed DED subjects had a significantly increased risk of low mental HR-QoL with increasing dry eye symptoms compared to diagnosed subjects (P < 0.0005). Compared to allergic conjunctivitis, glaucoma, macular degeneration and retinal detachment, DED showed the highest risk of low HR-QoL. Compared to other common systemic and chronic disorders, such as depression, rheumatoid arthritis, and COPD, DED was distinctive by having a substantial reduction in both PCS and MCS. DED is associated with substantial reductions in both physical and mental HR-QoL, also after correction for associated comorbidities. Not having a diagnosis is associated with worse mental HR-QoL in subjects with severe DED. Our results underline the importance of recognizing dry eye as a serious disorder.

1 October 2013 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
JVJelle Vehof
Jelle Vehof
DKDiana Kozareva
Diana Kozareva
PHPirro G. Hysi
Pirro G. Hysi
JHJuliette Harris
Juliette Harris
ANAyrun Nessa
Ayrun Nessa
CHChristopher J. Hammond
Christopher J. Hammond
Dry eye disease (DED) is a multifactorial disease of the tears that can potentially damage the ocular surface.1 It causes considerable morbidity, with symptoms of pain, irritation, and interference with normal visual tasks.2 Dry eye disease is a common problem, affecting 5% to 35% of middle-aged and elderly individuals, depending on the definition used.3-7 Women are at increased risk compared with men.5,6,8,9

1 April 2021 in The Ocular Surface
Verified
Journal Article
Open access
MMMorten Schjerven Magno
Morten Schjerven Magno
TUTor Paaske Utheim
Tor Paaske Utheim
HSHarold Snieder
Harold Snieder
CHChristopher J. Hammond
Christopher J. Hammond
JVJelle Vehof
Jelle Vehof
Sleep is an important determinant of health and quality of life. This study aimed to clarify the association between dry eye and sleep quality using a large population-based cohort. 71,761 participants (19-94 yrs, 59.4% female) from the Lifelines cohort in the Netherlands were assessed for dry eye using the Women's Health Study Dry Eye Questionnaire. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI). Logistic regression was used to examine the relationship between poor sleep quality (PSQI score >5) and dry eye, while correcting for age, sex, BMI, education, income, and 51 possible confounding comorbidities, including autoimmune diseases and psychiatric disorders. Overall, 8.9% of participants had dry eye. Of these, 36.4% had poor sleep quality compared to 24.8% of controls (OR 1.52 (95%CI 1.44-1.60), P < 0.0001, corrected for age and sex). After correcting for all comorbidities, dry eye was still associated with poor sleep (OR 1.20 (95%CI 1.11-1.28), P < 0.0001). This relationship was seen across all ages and sexes. Patients with dry eye scored worse on all subcomponents of the PSQI. Almost one-in-two (44.9%) persons with dry eye symptoms "often" or "constantly" had poor sleep quality. This proportion was similar to participants with sleep apnea and osteoarthritis. Additionally, increasing symptom frequency was tied to increased prevalence of poor sleep quality. All components of sleep quality were significantly reduced in participants with dry eye, even after correcting for comorbidities. These results indicate the substantial impact of dry eye on patients' lives, especially for those with frequent symptoms.